Molecular and Pharmacological Basis of Breast Cancer Resistance to Therapies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 109
Special Issue Editors
Interests: liquid biopsy; pharmacogenetics; ctDNA; treatment resistance; clinical pharmacology; personalized medicine
Interests: personalized medicine, pharmacogenetics, therapeutic drug monitoring, pharmacoeconomics, healthcare economics, clinical pharmacology
Special Issue Information
Dear Colleagues,
We would like to draw your attention to the importance of conducting comprehensive evaluations related to breast cancer within the context of our upcoming special issue, titled "Molecular and Pharmacological Basis of Breast Cancer Resistance to Therapies." In light of the profound impact of breast cancer on individuals, families, and society at large, we emphasize and prioritize the rigorous assessment of this disease.
Breast cancer remains a critical global health issue, affecting millions of individuals worldwide. In our quest for innovative solutions and improved treatment strategies, the evaluation of breast cancer takes on a central role. Importantly, the tumour genetic landscape influences treatment response in cancer patients. Multiple molecular mechanisms of resistance to therapies in breast cancer have been discussed, highlighting the degree of tumours’ heterogeneity.
This evaluation primarily focuses on:
- Resistance Mechanisms: Investigating the intricate molecular pathways and genetic factors that drive resistance to anticancer therapies in breast cancer is crucial for develo** more effective treatment approaches.
- Personalized Treatment Approaches: Evaluating the potential for tailoring breast cancer treatments based on individual patient characteristics and safety profiles is a key focus in our efforts to improve patient outcomes.
- We believe that by emphasizing these critical aspects of breast cancer evaluation, particularly the mechanisms underlying resistance to anticancer treatment, we can make significant strides in our collective mission to combat this disease.
I/We look forward to receiving your contributions.
Dr. Stefania Crucitta
Dr. Rossana Roncato
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- resistance mechanisms
- personalized treatment approaches
